中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

48 records (took 0.016 seconds)

    1-Methylamino-quinoline-carboxylic acid derivatives
    3.
    发明授权
    1-Methylamino-quinoline-carboxylic acid derivatives 失效
    1-甲基氨基 - 喹啉羧酸衍生物

    公开(公告)号：US4871849A

    公开(公告)日：1989-10-03

    申请号：US105299

    申请日：1987-06-24

    Applicant: Istvan Hermecz ,  Geza Kereszturi ,  Lelle Vasvavi ,  Agnes Horvath ,  Maria Balogh ,  Gabor Kovacs ,  Tamas Szuts ,  Peter Ritli ,  Judit Sipos ,  Aniko Pajor

    Inventor： Istvan Hermecz ,  Geza Kereszturi ,  Lelle Vasvavi ,  Agnes Horvath ,  Maria Balogh ,  Gabor Kovacs ,  Tamas Szuts ,  Peter Ritli ,  Judit Sipos ,  Aniko Pajor

    IPC: C07D401/02 ,  A61K31/47 ,  C07D20060101 ,  C07D215/00 ,  C07D215/56 ,  C07D215/58 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07F5/02

    CPC classification number: C07F5/022 ,  C07D215/58

    Abstract: The present invention relates to a process for the preparation of compounds of the general Formula I ##STR1## and pharmaceutically acceptable salts thereof (wherein R stands for piperazinyl or 4-methyl-piperazinyl) which comprises reacting a compound of the general Formula II ##STR2## (wherein R.sup.1 and R.sup.2 stand for halogen; an aliphatic acyloxy group comprising 2-6 carbon atoms and optionally substituted by halogen; or an aromatic acyloxy group comprising 7-11 carbon atoms) with a piperazine of the general Formula III ##STR3## (wherein R.sup.3 represent hydrogen or methyl) or a salt thereof, hydrolysing the compound of the general Formula IV ##STR4## thus obtained (wherein R, R.sup.1 and R.sup.2 are as stated above) without or after hydrolysis and if desired converting the compound of the general Formula I thus obtained into a salt thereof or setting free the same from its salt.The compounds of the general Formula I are known antibacterial agents.The advantage of the process of the present invention is that it enables the preparation of the compounds of the general Formula I in a simple manner, with high yields and in a short reaction time.

    Abstract translation: PCT No.PCT / HU86 / 00067 Sec。 371日期1987年6月24日 102（e）1987年6月24日PCT PCT日期：1986年12月9日PCT公布。 公开号WO87 / 03586 日期：1987年6月18日。本发明涉及一种制备通式I的化合物及其药学上可接受的盐（其中R代表哌嗪基或4-甲基 - 哌嗪基）的方法，其包括使 通式II的化合物（其中R1和R2代表卤素;包含2-6个碳原子并任选被卤素取代的脂族酰氧基或者包含7-11个碳原子的芳香酰氧基）与哌嗪 通式III III（其中R 3表示氢或甲基）或其盐，水解由此得到的通式IV的化合物（其中R，R 1和R 2如上所述），无 水解后，如果需要，将由此获得的通式I的化合物转化为其盐或使其与其盐相同。 通式I的化合物是已知的抗菌剂。 本发明方法的优点在于它能够以高产率和短的反应时间以简单的方式制备通式I的化合物。

    Quinoline carboxylic acid boric acid anhydrides
    6.
    发明授权
    Quinoline carboxylic acid boric acid anhydrides 失效
    喹啉羧酸硼酸酐

    公开(公告)号：US4940794A

    公开(公告)日：1990-07-10

    申请号：US290167

    申请日：1988-12-02

    Applicant: Istvan Hermecz ,  Geza Kereszturi ,  Lelle Vasvari ,  Agnes Horvath ,  Maria Halogh ,  Peter Ritli ,  Judit Sipos ,  Aniko Pajor ,  Katalin Marmarosi

    Inventor： Istvan Hermecz ,  Geza Kereszturi ,  Lelle Vasvari ,  Agnes Horvath ,  Maria Halogh ,  Peter Ritli ,  Judit Sipos ,  Aniko Pajor ,  Katalin Marmarosi

    IPC: C07D215/56 ,  A61K31/47 ,  A61P31/04 ,  C07D215/16 ,  C07D215/54 ,  C07F5/00 ,  C07F5/02 ,  C07F5/04

    CPC classification number: C07F5/04

    Abstract: The invention relates to new quinoline-3-carboxylic acid anhydride intermediates of the Formula I ##STR1## wherein R stands for cyclopropyl, a group of the Formula --CH.sub.2 CR.sup.5 R.sup.6 R.sup.7 wherein R.sup.5, R.sup.6 and R.sup.7 stand for hydrogen or halogen, or phenyl optionally substituted by 1 or 2 halogen,R.sup.1 and R.sup.2 stand for halogen, or an aliphatic acyloxy group containing 2 to 6 carbon atoms optionally substituted by halogen, or an aromatic acyloxy group containing 7 to 11 carbon atoms,R.sup.3 stands for chlorine or fluorine andR.sup.4 stands for hydrogen or fluorine. The compounds of the Formula I are new intermediates for the preparation of known quinoline-3-carbocxylic acids showing antibacterial activity.

    Abstract translation: PCT No.PCT / HU88 / 00018 Sec。 371日期：1988年12月2日 102（e）日期1988年12月2日PCT提交1988年4月8日PCT公布。 出版物WO88 / 07998 日本公开号为1988年10月20日。本发明涉及式I（I）的新型喹啉-3-羧酸酐中间体，其中R代表环丙基，式-CH 2 CR 5 R 6 R 7基团，其中R5，R6和R7表示 对于氢或卤素，或任选被1或2个卤素取代的苯基，R 1和R 2代表卤素，或任选被卤素取代的含2至6个碳原子的脂族酰氧基或含有7至11个碳原子的芳族酰氧基， R3代表氯或氟，R4代表氢或氟。 式I化合物是制备显示抗菌活性的已知喹啉-3-羧酸的新中间体。

    Condensed pyrimidines
    8.
    发明授权
    Condensed pyrimidines 失效
    浓缩嘧啶

    公开(公告)号：US4495189A

    公开(公告)日：1985-01-22

    申请号：US364753

    申请日：1982-04-02

    Applicant: Zoltan Meszaros ,  Jozsef Knoll ,  Peter Szentmiklosi ,  Istvan Hermecz ,  Agnes Horvath ,  Sandor Virag ,  Lelle Vasvari ,  Agoston David

    Inventor： Zoltan Meszaros ,  Jozsef Knoll ,  Peter Szentmiklosi ,  Istvan Hermecz ,  Agnes Horvath ,  Sandor Virag ,  Lelle Vasvari ,  Agoston David

    IPC: C07D471/04 ,  A61K31/505

    CPC classification number: C07D471/04

    Abstract: New compounds of the following formula are disclosed:1,6-dimethyl-3-carbamoyl-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)-pyrimidine;1,6-dimethyl-3-(N-tertiary-butyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine;1,6-dimethyl-3-(N-2-phenethyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine;1,6-dimethyl-3-[N-(3,3-diphenyl-propyl)-carbamoyl]-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine;1,6-dimethyl-3-(N-phenyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine; and1,6-dimethyl-3-(N-methyl-carbamoyl)-4-oxo-1,6,7,8-tetrahydro-4H-pyrido(1,2-a)pyrimidine, as well as pharmaceutical compositions containing these compounds and a method of inhibiting thrombocyte aggregation in mammals employing a pharmaceutically effective amount of at least one of these compounds.

    Abstract translation: 公开了下式的新化合物：1,6-二甲基-3-氨基甲酰基-4-氧代-1,6,7,8-四氢-4H-吡啶并（1,2-a） - 吡啶亚胺; 1,6-二甲基-3-（N-叔丁基 - 氨基甲酰基）-4-氧代-1,6,7,8-四氢-4H-吡啶并（1,2-a）嘧啶; 1,1-二甲基-3-（N-2-苯乙基 - 氨基甲酰基）-4-氧代-1,6,7,8-四氢-4H-哒嗪（1,2-a）嘧啶; 1,6-二甲基-3- [N-（3,3-二苯基 - 丙基） - 氨基甲酰基] -4-氧代-1,6,7,8-四氢-4H-吡啶并（1,2-a）嘧啶 ; 1,6-二甲基-3-（N-苯基 - 氨基甲酰基）-4-氧代-1,6,7,8-四氢-4H-吡啶并（1,2-a）嘧啶; 和1,6-二甲基-3-（N-甲基 - 氨基甲酰基）-4-氧代-1,6,7,8-四氢-4H-吡啶并（1,2-a）嘧啶，以及含有这些的药物组合物 化合物和使用药学上有效量的这些化合物中的至少一种来抑制哺乳动物血小板聚集的方法。

    Nitrogen bridgehead compounds having anti-allergic effect
    9.
    发明授权
    Nitrogen bridgehead compounds having anti-allergic effect 失效
    具有抗过敏作用的氮桥头头合成物

    公开(公告)号：US4461769A

    公开(公告)日：1984-07-24

    申请号：US76811

    申请日：1979-09-19

    Applicant: Istvan Hermecz ,  Zoltan Meszaros ,  Tibor Breining ,  Sandor Virag ,  Lelle Vasvari nee Debreczy ,  Agnes Horvath ,  Gabor Nagy ,  Attila Mandi ,  Tamas Szucs ,  Istvan Bitter ,  Gyula Sebestyen

    Inventor： Istvan Hermecz ,  Zoltan Meszaros ,  Tibor Breining ,  Sandor Virag ,  Lelle Vasvari nee Debreczy ,  Agnes Horvath ,  Gabor Nagy ,  Attila Mandi ,  Tamas Szucs ,  Istvan Bitter ,  Gyula Sebestyen

    IPC: A61K31/505 ,  A61K31/519 ,  A61P1/04 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P25/00 ,  A61P25/04 ,  A61P25/20 ,  A61P29/00 ,  A61P31/04 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04

    CPC classification number: C07D471/04 ,  Y10S514/826

    Abstract: Compounds of the formula I ##STR1## or pharmaceutically acceptable salts, hydrates, stereoisomers, optically active isomers, geometrical isomers or tautomeric forms thereof are disclosedwhereinR is hydrogen or lower alkylR.sup.1 is hydrogen, lower alkyl, styryl, or a carboxylic acid; orR and R.sup.1 together form a group of the formula --(CH.dbd.CH).sub.2 -- and in this case the broken line represents a further C--C bond, while in all other cases there is a single bond between positions 6 and 7;R.sup.2 is hydrogen, lower alkyl or hydroxy;R.sup.3 is hydrogen, lower alkyl, aryl, lower alkanoyl, carboxyl or a carboxyl acid derivative or a group of the formula --(CH.sub.2)m--COOH or a derivative thereof formed in the carboxylic group;n=1-3;R.sup.4 is hydrogen, lower alkyl which can be substituted by hydroxy or carboxy; trifluoromethyl, substituted or unsubstituted aryl, phenyl-lower alkyl or substituted or an unsubstituted heterocyclic group;R.sup.5 is hydrogen, lower alkanoyl, substituted or unsubstituted benzoyl or heteroaryl; orR.sup.4 and R.sup.5 together with the adjacent nitrogen atom form a piperidino, pyrrolidino or morpholino ring; orR.sup.4 and R.sup.5 together with the adjacent nitrogen atom form a group of the formula ##STR2## wherein R.sup.6 is hydrogen and R.sup.7 is substituted or unsubstituted phenyl; andZ is oxygen. The new compounds are useful for treating asthma.

    Abstract translation: 公开了式I的化合物或其药学上可接受的盐，水合物，立体异构体，光学活性异构体，几何异构体或互变异构体，其中R是氢或低级烷基R 1是氢，低级烷基，苯乙烯基或羧酸; 或R和R 1一起形成式 - （CH = CH）2 - 的基团，在这种情况下，虚线代表另外的C-C键，而在所有其它情况下，位置6和7之间存在单键; R2是氢，低级烷基或羟基; R3是在羧基中形成的氢，低级烷基，芳基，低级烷酰基，羧基或羧基酸衍生物或式 - （CH2）m-COOH或其衍生物的基团; n = 1-3; R4是氢，可被羟基或羧基取代的低级烷基; 三氟甲基，取代或未取代的芳基，苯基 - 低级烷基或取代或未取代的杂环基; R5是氢，低级烷酰基，取代或未取代的苯甲酰基或杂芳基; 或R4和R5与相邻的氮原子一起形成哌啶子基，吡咯烷子基或吗啉代环; 或R 4和R 5与相邻的氮原子一起形成下式的基团：其中R6是氢，R7是取代或未取代的苯基; Z是氧。 新化合物可用于治疗哮喘。

    Process for the preparation of 9-hydrazono-6,7,8,9-tetrahydro-4H-pyro[1,2-a]pyrimidine-4-one compounds, the salts and hydrates thereof
    10.
    发明授权
    Process for the preparation of 9-hydrazono-6,7,8,9-tetrahydro-4H-pyro[1,2-a]pyrimidine-4-one compounds, the salts and hydrates thereof 失效
    制备9-亚肼基-6,7,8,9-四氢-4H-焦[1,2-a]嘧啶-4-酮化合物的方法，其盐和水合物

    公开(公告)号：US4456752A

    公开(公告)日：1984-06-26

    申请号：US327689

    申请日：1981-12-04

    Applicant: Istvan Hermecz ,  Tibor Breining ,  Lelle Vasvari nee Debreczy ,  Agnes Horvath ,  Jozsef Kokosi

    Inventor： Istvan Hermecz ,  Tibor Breining ,  Lelle Vasvari nee Debreczy ,  Agnes Horvath ,  Jozsef Kokosi

    IPC: A61K31/505 ,  A61P11/00 ,  A61P37/08 ,  C07D471/04

    CPC classification number: C07D471/04

    Abstract: A process for the preparation of nitrogen bridgehead condensed pyrimidine compounds of the general formula ##STR1## [wherein R represents hydrogen or lower alkyl;R.sup.1 represents hydrogen, lower alkyl, carboxy or a derivative thereof or styryl;R.sup.2 represents hydrogen or optionally substituted lower alkyl;R.sup.3 represents hydrogen, optionally substituted lower alkyl, aryl, aralkyl, halogen, carboxy or a derivative thereof, the group --(CH.sub.2).sub.m --COOH (in which m is the integer 1, 2 or 3) or a carboxy derivative thereof, formyl, lower alkanoyl or a condensed thereof;R.sup.4 represents hydrogen, optionally substituted alkyl, aryl optionally substituted by one or more substituents, optionally substituted aralkyl, a heterocyclic group optionally substituted by one or more substituents, the group (CH.sub.2).sub.m --Het (in which m is the integer 1, 2 or 3; Het is an optionally substituted heterocyclic group);R.sup.5 represents hydrogen, C.sub.1-6 alkyl, aryl optionally substituted by one or more substituents, formyl, lower alkanoyl, optionally substituted aroyl or heteroaryl; orR.sup.4 and R.sup.5 together with the nitrogen therebetween represent an optionally substituted mono- or bicyclic heterocyclic ring optionally containing further heteroatom]and pharmaceutically acceptable salts, hydrates, stereoisomers, optically active isomers, geometrical isomers and tautomers thereof.

    Abstract translation: 制备通式为“IMAGE”I的氮桥头浓缩嘧啶化合物的方法[其中R表示氢或低级烷基; R1代表氢，低级烷基，羧基或其衍生物或苯乙烯基; R 2表示氢或任选取代的低级烷基; R 3表示氢，任选取代的低级烷基，芳基，芳烷基，卤素，羧基或其衍生物，基团 - （CH 2）m -COOH（其中m是整数1,2或3）或其羧基衍生物， ，低级烷酰基或其缩合物; R 4表示氢，任选取代的烷基，任选被一个或多个取代基取代的芳基，任选取代的芳烷基，任选被一个或多个取代基取代的杂环基，基团（CH 2）m -Het（其中m是整数1,2 或3; Het是任选取代的杂环基）; R 5表示氢，C 1-6烷基，任选被一个或多个取代基取代的芳基，甲酰基，低级烷酰基，任选取代的芳酰基或杂芳基; 或R4和R5以及它们之间的氮代表任选地被取代的单环或双环杂环，任选地含有另外的杂原子]及其药学上可接受的盐，水合物，立体异构体，光学活性异构体，几何异构体和互变异构体。

Patent Agency Ranking